Ovintiv Inc. (OVV)

Negative revenue growth while CVE stands at 19.40%. Joel Greenblatt would look for strategic missteps or cyclical reasons.

Negative gross profit growth while CVE is at 119.11%. Joel Greenblatt would examine cost competitiveness or demand decline.

Negative EBIT growth while CVE is at 268.54%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Negative operating income growth while CVE is at 268.54%. Joel Greenblatt would press for urgent turnaround measures.

Net income growth under 50% of CVE's 118.86%. Michael Burry would suspect the firm is falling well behind a key competitor.

EPS growth under 50% of CVE's 117.44%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.

Diluted EPS growth under 50% of CVE's 117.44%. Michael Burry would worry about an eroding competitive position or excessive dilution.

Share count expansion well above CVE's 6.68%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.

Diluted share count expanding well above CVE's 6.38%. Michael Burry would fear significant dilution to existing owners' stakes.

Negative OCF growth while CVE is at 21.82%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

Negative FCF growth while CVE is at 91.34%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.

Negative 10Y revenue/share CAGR while CVE stands at 19.30%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.

Negative 5Y CAGR while CVE stands at 3.32%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.

Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.

Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.

Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.

Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.

Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

Negative 5Y equity/share growth while CVE is at 0.10%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Below 50% of CVE's 1.48%. Michael Burry suspects a serious short-term disadvantage in building book value.

Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.

Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.

Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.

Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.

Inventory growth well above CVE's 3.28%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.

Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.

Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.

Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.